Tonix Pharmaceuticals Holding Corp.

509 Madison Avenue, Suite 1608

New York, New York 10022

 

 July 9, 2019

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-1 (File No. 333-232195)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on July 11, 2019, or as soon as practicable thereafter.

 

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature page follows.]

 

 
 

 

U.S. Securities and Exchange Commission
July 9, 2019
Page 2

 

 

  Very truly yours,
   
  TONIX PHARMACEUTICALS
  HOLDINGS CORP.
   
   
  By:  /s/ Bradley Saenger
 

Name:

Title:

Bradley Saenger
Chief Financial Officer